FMP
Soleno Therapeutics, Inc.
SLNO
NASDAQ
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
45.18 USD
-0.02 (-0.04427%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Anish Bhatnagar M.D.
sector
Healthcare
industry
Biotechnology
website
https://soleno.lifeexchange
NASDAQ
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
CIK
0001484565
ISIN
US8342033094
CUSIP
834203200
Address
203 Redwood Shores Parkway
Phone
650 213 8444
Country
US
Employee
33
IPO Date
Nov 13, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
SLNO Financial Summary
CIK
0001484565
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
834203200
ISIN
US8342033094
Country
US
Price
45.18
Beta
-1.44
Volume Avg.
681.96k
Market Cap
1.95B
Shares
-
52-Week
35.7-60.92
DCF
10.26
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-16.19
P/B
-
Website
https://soleno.life
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SLNO News
It looks like there's no news available.
